-
公开(公告)号：US20180222982A1
公开(公告)日：2018-08-09
申请号：US15747873
申请日：2016-07-28
申请人： Glenn Dranoff , Gordon James Freeman , Arlene Helen Sharpe , Walter A. Blattler , Jennifer Marie Mataraza , Catherine Anne Sabatos-Peyton , Hwai Wen Chang , Gerhard Johann Frey , Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： Glenn Dranoff , Gordon James Freeman , Arlene Helen Sharpe , Walter A. Blattler , Jennifer Marie Mataraza , Catherine Anne Sabatos-Peyton , Hwai Wen Chang , Gerhard Johann Frey
IPC分类号： C07K16/28 , A61P35/00 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/00 , A61K39/39541 , A61K2039/505 , A61P35/00 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： Combination therapies comprising antibody molecules that specifically bind to PD-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
-
公开(公告)号：US20120183565A1
公开(公告)日：2012-07-19
申请号：US13388028
申请日：2010-07-26
申请人： Jennifer Marie Mataraza , Andrea Van Elsas , Alan J. Korman , Edward L. Halk , Kent B. Thudium , Mark Selby , Timothy W. Sproul , Heidi N. Leblanc
发明人： Jennifer Marie Mataraza , Andrea Van Elsas , Alan J. Korman , Edward L. Halk , Kent B. Thudium , Mark Selby , Timothy W. Sproul , Heidi N. Leblanc
IPC分类号： A61K39/395 , C12N15/63 , C12N1/21 , C12N5/10 , C12P21/02 , A61P29/00 , A61P37/06 , A61P1/00 , A61P1/04 , A61P11/00 , A61P19/02 , A61P19/10 , A61P11/06 , A61P37/08 , A61P25/00 , A61P17/06 , A61P27/02 , A61P3/10 , A61P37/04 , C12N15/13 , A61P17/00 , C07K16/24
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
摘要翻译： 本发明涉及对BTLA特异性的结合化合物及其用途。 更具体地，本发明涉及识别人BTLA并调节其在癌症，炎性和自身免疫性疾病中的活性的完全人抗体。
-
3.发明申请公开(公告)号：US20190000944A1
公开(公告)日：2019-01-03
申请号：US16065387
申请日：2016-12-21
申请人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe , Novartis AG , The Trustees of the University of Pennsylvania , DANA-FARBER CANCER INSTITUTE, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe
IPC分类号： A61K39/00 , A61K39/395 , A61P35/00 , A61K45/06
摘要： Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
-
公开(公告)号：US20180207273A1
公开(公告)日：2018-07-26
申请号：US15747326
申请日：2016-07-28
申请人： Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu , Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , Children's Medical Center Corporation
发明人： Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC分类号： A61K39/395 , A61K45/06 , A61P35/00
CPC分类号： A61K39/39566 , A61K39/00 , A61K39/3955 , A61K45/06 , A61K2039/507 , A61P35/00 , C07K16/2803 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/94 , A61K2300/00
摘要： Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
-
公开(公告)号：US08563694B2
公开(公告)日：2013-10-22
申请号：US13388028
申请日：2010-07-26
申请人： Jennifer Marie Mataraza , Andrea Van Elsas , Alan J. Korman , Edward L. Halk , Kent B. Thudium , Mark Selby , Timothy W. Sproul , Heidi N. Leblanc
发明人： Jennifer Marie Mataraza , Andrea Van Elsas , Alan J. Korman , Edward L. Halk , Kent B. Thudium , Mark Selby , Timothy W. Sproul , Heidi N. Leblanc
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
摘要翻译： 本发明涉及对BTLA特异性的结合化合物及其用途。 更具体地，本发明涉及识别人BTLA并调节其在癌症，炎性和自身免疫性疾病中的活性的完全人抗体。
-
-
-
-
搜索结果
5 条记录 (耗时 0.033 秒)
